• Olivier Brocq, Emilie Acquacalda, Frédéric Berthier, Christine Albert, Gilles Bolla, Elodie Millasseau, Claire Destombe, Johanna Azulay, Caroline Asquier, Amélie Florent, Sylvie Le Seaux, and Liana Euller-Ziegler.
• Rhumatologie, centre hospitalier Princesse Grâce, boulevard Pasteur, 98000 Monaco, Monaco. Electronic address: obrocq@chpg.mc.
• Joint Bone Spine. 2016 Mar 1; 83 (2): 155-9.

ObjectivesTo evaluate influenza and pneumococcal vaccine coverage in patients taking biological therapy for chronic inflammatory joint disease and to identify factors associated with the decision to administer these two vaccines.MethodsRetrospective cross-sectional questionnaire study of a cohort of 584 patients taking biological therapy for chronic inflammatory joint disease (rheumatoid arthritis or spondyloarthritis). We studied the influenza and pneumococcal vaccine coverage rates, information about these vaccines given to patients by the primary-care physician and rheumatologist, and reasons for not administering the vaccines.ResultsOverall vaccine coverage rates were 44% for influenza and 62% for pneumococcus. Factors associated with being vaccinated were patient age, previous influenza vaccination, and patient information. Concern about adverse effects and absence of patient information by the primary-care physician and rheumatologist were associated with very low coverage rates.ConclusionThis study showed insufficient vaccine coverage rates, particularly against influenza, in a population at high risk because of exposure to biological therapy. Patient information by healthcare professionals about influenza and pneumococcal vaccination has a major impact and should be renewed as often as possible.Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

31 keywords...

hide…